Skip to main navigation Skip to search Skip to main content

A Phase 3 Randomized, Double Blind, Placebo-Controlled Parallel Group Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active UC (UNIFI)

Grants and Contracts Details

StatusFinished
Effective start/end date3/31/16 → 6/30/18

Funding

  • Janssen Research and Development LLC: $14,696.00